Endothelix Licenses New Ultrasound Doppler Technology from UC Berkeley


Houston
, TX – February 15th, 2007: Houston-based Endothelix, Inc. has acquired new intellectual property from the University of California Berkeley that expands its technology platform to include the most advanced Thermo-Doppler monitoring of vascular function.

 

The agreement between Endothelix Inc., and the Ernest Orlando Lawrence Berkeley National Laboratory transfers ultrasonic pulse transit time monitoring of endothelial function in conduit arteries to Endothelix’s growing patent portfolio.

 

The exclusive license will complement Endothelix’s DTM (digital thermal monitoring) technology and further the company’s quest to provide a comprehensive vascular function monitoring system that is noninvasive, low-cost, and operator independent.

 

“We are pleased that UC Berkeley has found Endothelix as the right partner for commercialization of its endothelial function measurement technology” said Dr. Morteza Naghavi, CEO and President of Endothelix. “The addition of this technology ensures Endothelix’s leadership as the only company to provide a comprehensive micro and macro vascular function monitoring device.”

 

The invention came from the laboratory of Drs. Thomas Budinger and Jonathan Maltz, who serve as scientific advisors to Endothelix. The laboratory is well known for pioneering several breakthrough cardiovascular technologies.

 

“Endothelial function monitoring is the next big thing in cardiovascular diagnostics, much like blood pressure monitoring 50 years ago. We are very pleased to help Endothelix in its mission for transferring endothelial function measurement from research laboratories to patient care,” said Dr. Budinger, Professor and Chair Emeritus, Department of Bioengineering, University of California, Berkeley.

 

Cardiovascular disease is the number one killer in the US. The American Heart Association estimates over 70 million Americans have at least one form of cardiovascular disease – most of whom have no signs or symptoms.

 

While new effective therapies are increasingly available, early detection of asymptomatic patients and monitoring of their response to various therapies remains a major challenge. Current modalities for screening cardiovascular disease and monitoring effectiveness of therapies are limited to measurement of traditional risk factors such cholesterol and blood pressure or non-invasive imaging technologies such as CAT scan and MRI.

 

Traditional risk factors are inadequate for vascular health measurement, and noninvasive imaging technologies are expensive or impose hazardous radiation therefore cannot be repeated often and do not show progression or regression of patients in short time.

 

Endothelix is striving to fill in the gap and bring to practice non-invasive, non-imaging techniques capable of monitoring vascular function that are simple, inexpensive, operator independent, and easily repeatable for screening and monitoring response to therapy.

 

“Ultrasound Doppler technology is safe, non-invasive, and relatively inexpensive. It has enormous potential to help physicians improve patient care,” said Dr. Craig J. Hartley, a world-renowned expert in Doppler ultrasound, a professor of medicine at Baylor College of Medicine and an Endothelix advisor. “With the new Thermo-Doppler technology, we should be able to detect vascular dysfunction in small resistance vessels as well as in large conduit arteries”

 

Endothelial function is regarded as a “barometer” of cardiovascular health.  In addition to heart attack and stroke, impaired endothelial function is associated with diabetes, heart failure, kidney disease, and Alzheimer’s.  Endothelix has positioned itself as the first endothelial function monitoring company with comprehensive Micro and Macro vascular endothelial function monitoring technologies. The company is growing its IP portfolio to maintain its leadership.
 
 

 

About Endothelix:

Endothelix is a Delaware corporation based in Houston, Texas and was formed in December 2003. The company is dedicated to promoting vascular endothelial health. The company’s products are designed to enable practicing physicians to regularly monitor their patient’s endothelial function and to use appropriate therapies for treatment of endothelial dysfunction. The initial focus of the company is to bring endothelial function measurement to the mainstream practice of medicine, in a low-cost widely reproducible manner. The immediate application of the company’s first line of product is tailored to cardiovascular healthcare particularly for prevention of heart attack and stroke. More information is available at www.endothelix.com.

 

Author: Craig Jamieson
Phone: (713) 529-2599
Email:
Category: client companies | Sub Category: life sciences